Arkolith/Insider Trading/ABOS/Form 4

OConnell Daniel Joseph

Chief Executive Officer, DirectorAcumen Pharmaceuticals, Inc. (ABOS) · full profile →Form 4 · filed Jan 23, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$22K
Net Open-Market Flow
-$22K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 22, 2026Sell(S)3K$1.88$5K881K
Jan 21, 2026Sell(S)9K$1.81$17K884K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-003346) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML